Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Open accessAbstract
Alzheimer disease (AD) is characterized by β-amyloid (Aβ) plaques and tau neurofibrillary tangles. There are several PET imaging biomarkers for Aβ including 11C-PiB and 18F-florbetapir. Recently, PET tracers for tau neurofibrillary tangles have become available and have shown utility in detection and monitoring of neurofibrillary pathology over time. Flortaucipir F 18 is one such tracer. Initial clinical studies indicated greater tau binding in AD and mild cognitive impairment patients than in controls in a pattern consistent with tau pathology observed at autopsy. However, little is known about the reproducibility of such findings. To our knowledge, this study reports the first data regarding test–retest reproducibility of flortaucipir F 18 PET. Methods: Twenty-one subjects who completed the study (5 healthy controls, 6 mild cognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min beginning 80 min after injection and again at 110 min after injection. Follow-up (retest) imaging occurred between 48 h and 4 wk after initial imaging. Images were spatially normalized to Montreal Neurological Institute template space. SUVRs were calculated using AAL (Automated Anatomical Labeling atlas) volumes of interest (VOIs) for parietal, temporal, occipital, anterior, and posterior hippocampal, parahippocampal, and fusiform regions, as well as a posterior neocortical VOI composed of average values from parietal, temporal, and occipital areas. Further, a VOI derived by discriminant analysis that maximally separated diagnostic groups (multiblock barycentric discriminant analysis [MUBADA]) was used. All VOIs were referenced to a subsection of cerebellar gray matter (cere-crus) as well as a parametrically derived white matter–based reference region (parametric estimate of reference signal intensity [PERSI]). t test, correlation analyses, and intraclass correlation coefficient were used to explore test–retest performance. Results: Test–retest analyses demonstrated low variability in flortaucipir F 18 SUVR. The SD of mean percentage change between test and retest using the PERSI reference region was 2.22% for a large posterior neocortical VOI, 1.84% for MUBADA, 1.46% for frontal, 1.98% for temporal, 2.28% for parietal, and 3.27% for occipital VOIs. Further, significant correlations (R2 > 0.85; P < 0.001) were observed for all regions, and intraclass correlation coefficient values (test–retest consistency) were greater than 0.92 for all regions. Conclusion: Significant test–retest reproducibility for flortaucipir F 18 was found across neocortical and mesial temporal lobe structures. These preliminary data suggest that flortaucipir F 18 tau imaging could be used to examine changes in tau burden over time.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Flortaucipir is being developed as a positron emission tomography tracer for detection of the aggregated tau of Alzheimer disease.
“Flortaucipir is being developed as a PET tracer for detection of the aggregated tau of AD.19,21,22,23,24”
From Positron Emission Tomography Imaging With [ <sup>18</sup> F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · see citing works
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works
Unbiased nonlinear average age-appropriate brain templates from birth to adulthood
Fonov, V., Evans, A., McKinstry, R. C., Almli, C. R., & Collins, D. L. (2009) · NeuroImage · doi:10.1016/s1053-8119(09)70884-5 · Cited by 2,092 · see citing works
Partial Least Squares (PLS) methods for neuroimaging: A tutorial and review
Krishnan, A., Williams, L. J., McIntosh, A. R., & Abdi, H. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.07.034 · Cited by 1,335 · see citing works
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works
Goedert, M., Spillantini, M. G., Cairns, N. J., & Crowther, R. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90117-v · Cited by 1,114 · see citing works
Partial least squares analysis of neuroimaging data: applications and advances
McIntosh, A. R., & Lobaugh, N. J. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.020 · Cited by 1,084 · see citing works
Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease
KIDD, M. (1963) · Nature · doi:10.1038/197192b0 · Cited by 1,012 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760 · see citing works
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · see citing works
Erlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., & Hutton, B. F. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/r119 · Cited by 731 · see citing works
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 676 · see citing works
Self-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1× · see citing works
“A third group described the 5H-pyrio[4,3-b] indole (formerly 18F-T807, later named 18F-AV1451, flortaucipir F 18) as a potential PET tracer for detection of tau pathology (17,18).”
BackgroundSelf-citationVandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 649 · see citing works
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499 · see citing works
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · see citing works
Self-citationβ-Amyloid burden in healthy aging: Regional distribution and cognitive consequences
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., Mathews, D., & Park, D. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318245d295 · Cited by 419 · see citing works
Self-citationJoshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.090340 · Cited by 391 · see citing works
Self-citationAmyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 374 · see citing works
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357 · see citing works
Self-citationThomas, B. A., Erlandsson, K., Marc Modat, A., Thurfjell, L., Vandenberghe, R. R., Sebastien Ourselin, A., & Hutton, B. F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1745-9 · Cited by 317 · see citing works
Okamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero‐Tavoletti, M. T., Mulligan, R. S., Villemagne, V. L., Akatsu, H., Yamamoto, T., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.117341 · Cited by 289 · see citing works
Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET
Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 266 · see citing works
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt231 · Cited by 237 · see citing works
Clinical Validation of 18 F-AZD4694, an Amyloid-β–Specific PET Radioligand
Cselényi, Z., Eriksdotter, M., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnström, P., Varnäs, K., Svensson, S., & Farde, L. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094029 · Cited by 225 · see citing works
Dickson, D. W. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00065-1 · Cited by 168 · see citing works
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
Chiotis, K., Saint‐Aubert, L., Savitcheva, I., Jelić, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A. E., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3363-z · Cited by 127 · see citing works
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99 · cited 2× · see citing works
“There is, however, a modest literature on this topic for amyloid imaging tracers (38).”
BackgroundTau aggregation in the hippocampal formation: an ageing or a pathological process?
Delacourte, A., Sergeant, N., Wattez, A., Maurage, C., Lebert, F., Pasquier, F., & David, J. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00141-9 · Cited by 98 · see citing works
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 96 · see citing works
Shcherbinin, S., Schwarz, A. J., Joshi, A. D., Navitsky, M. A., Flitter, M. L., Shankle, W. R., Devous, M. D., & Mintun, M. A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170027 · Cited by 93 · see citing works
Self-citationOne Hundred Years after the Discovery of Alzheimer's Disease. A Turning Point for Therapy?
Giacobini, E., & Becker, R. E. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12105 · Cited by 92 · see citing works
Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.
Southekal, S., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Mintun, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200006 · Cited by 92 · see citing works
Self-citationTest-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease
Tolboom, N., Yaqub, M. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1129-6 · Cited by 76 · see citing works
Abdi, H., Williams, L. J., Beaton, D., Posamentier, M. T., Harris, T. S., Krishnan, A., & Devous, M. D. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112111 · Cited by 35 · see citing works
Self-citationA Clinical Perspective: Anti Taus Treatment in Alzheimers Disease
Fuentes, P., & Catalan, J. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717221 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Fuentes P, Catalan J. A clinical perspective: anti tau's treatment in Alzheimer's disease. Curr Alzheimer Res. 2011;8:686-688.
- Murray ME, Kouri N, Lin WL, Jack CR Jr, Dickson DW, Vemuri P. Clinico- pathologic assessment and imaging of tauopathies in neurodegenerative demen- tias. Alzheimers Res Ther. 2014;6:1-13.
Cited by
Sorted by citations
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · see citing works
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · see citing works
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761 · see citing works
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580 · see citing works
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450 · see citing works
Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · see citing works
Self-citationRadiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 283 · see citing works
Neuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289 · see citing works
“92 across all regions tested, which indicates high test-retest reliability and suggests that this method can be used to detect changes in tau burden over time [45].”
MethodPontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249 · see citing works
Self-citationSchöll, M., Maaß, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. J. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 227 · see citing works
Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2793 · Cited by 210 · see citing works
Self-citationThe development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 183 · see citing works
McCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. D. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 121 · see citing works
Direct Comparison of the Tau PET Tracers18F-Flortaucipir and18F-MK-6240 in Human Subjects
Gogola, A., Minhas, D. S., Villemagne, V. L., Cohen, A. D., Mountz, J. M., Pascoal, T. A., Laymon, C. M., Mason, N. S., Ikonomović, M. D., Mathis, C. A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254961 · Cited by 97 · see citing works
Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study
Cho, H., Choi, J. Y., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., Jack, C. R., & Lyoo, C. H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221697 · Cited by 94 · see citing works
Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity.
Southekal, S., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Joshi, A. D., Pontecorvo, M. J., & Mintun, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200006 · Cited by 92 · see citing works
Self-citationDhaynaut, M., Sprugnoli, G., Cappon, D., Macone, J., Sanchez, J. S., Normandin, M. D., Guehl, N. J., Koch, G., Paciorek, R., Connor, A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215072 · Cited by 79 · see citing works
Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial
Viña, J., Escudero, J. V., Baquero, M., Cebrián, M., Carbonell‐Asins, J. A., Muñoz, J. E., Satorres, E., Meléndez, J. C., Ferrer-Rebolleda, J., Cozar, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01097-2 · Cited by 74 · see citing works
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 66 · see citing works
Topographic staging of tau positron emission tomography images
Schwarz, A. J., Shcherbinin, S., Slieker, L. J., Risacher, S. L., Charil, A., Irizarry, M. C., Fleisher, A., Southekal, S. S., Joshi, A. D., Devous, M. D., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.006 · Cited by 62 · see citing works
Self-citationTian, M., Zuo, C., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., et al. (2022) · Phenomics · doi:10.1007/s43657-022-00068-9 · Cited by 52 · see citing works
Bollack, A., Pemberton, H., Collij, L. E., Markiewicz, P. J., Cash, D. M., Farrar, G., & Barkhof, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13158 · Cited by 49 · see citing works
Assessment of Efficacy and Safety of Zagotenemab
Fleisher, A., Munsie, L. M., David, P., Andersen, S. W., Higgins, I. A., Hauck, P. M., Lo, A., Sims, J. R., Bryś, M., Mintun, M. A., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000208061 · Cited by 47 · see citing works
Self-citationWolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Hansson, O., Nordberg, A. K., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 47 · see citing works
What’s the cut-point?: a systematic investigation of tau PET thresholding methods
Weigand, A. J., Maaß, A., Eglit, G. L., & Bondi, M. W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00986-w · Cited by 44 · see citing works
Wang, M.-L., Yu, M., Wei, X., Li, W., & Li, Y. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.014 · Cited by 43 · see citing works
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3
Yaari, R., Holdridge, K. C., Williamson, M., Wessels, A. M., Shcherbinin, S., Kotari, V., Reiman, E. M., Tariot, P. N., Alexander, R., Langbaum, J. B. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70662 · Cited by 42 · see citing works
Schwarz, C. G., Therneau, T. M., Weigand, S. D., Gunter, J. L., Lowe, V. J., Przybelski, S. A., Senjem, M. L., Botha, H., Vemuri, P., Kantarci, K., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118259 · Cited by 41 · see citing works
Devous, M. D., Fleisher, A., Pontecorvo, M. J., Lu, M., Siderowf, A. D., Navitsky, M. A., Kennedy, I. A., Southekal, S. S., Harris, T. S., & Mintun, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200808 · Cited by 37 · see citing works
Self-citationTimmers, T., Ossenkoppele, R., Visser, D., Tuncel, H., Wolters, E. E., Verfaillie, S. C. J., van der Flier, W. M., Boellaard, R., Golla, S. S. V., & van Berckel, B. N. M. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879226 · Cited by 32 · see citing works
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 29 · see citing works
Self-citationMohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 28 · see citing works
Sato, S., Hatakeyama, N., Fujikoshi, S., Katayama, S., Katagiri, H., & Sims, J. R. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00604-x · Cited by 28 · see citing works
Li, Y., Ng, Y. L., Paranjpe, M. D., Ge, Q., Gu, F., Li, P., Yan, S., Lu, J., Wang, X., Zhou, Y., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25774 · Cited by 25 · see citing works
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 23 · see citing works
Self-citationKlenner, M. A., Pascali, G., Fraser, B. H., & Darwish, T. A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.011 · Cited by 19 · see citing works
Jiao, F., Wang, M., Sun, X., Ju, Z., Lu, J., Wang, L., Jiang, J., & Zuo, C. (2023) · Brain Sciences · doi:10.3390/brainsci13020367 · Cited by 19 · see citing works
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
Gueorguieva, I., Willis, B. A., Chua, L., Chow, K. H., Ernest, C. S., Wang, J., Shcherbinin, S., Sims, J. R., & Chigutsa, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12404 · Cited by 19 · see citing works
Considerations for Use of Blood-Based Biomarkers in Epidemiologic Dementia Research
Hayes‐Larson, E., Ackley, S. F., Turney, I. C., Joie, R. L., Mayeda, E. R., Glymour, M. M., & Initiative, A. D. N. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad197 · Cited by 18 · see citing works
Willis, B. A., Lo, A., Dage, J. L., Shcherbinin, S., Chinchen, L., Andersen, S. W., LaBell, E. S., David, P., Hauck, P. M., & Lowe, S. L. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230012 · Cited by 17 · see citing works
Zhang, H., Wang, M., Lu, J., Bao, W., Li, L., Jiang, J., Zuo, C., & Initiative, A. A. D. N. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.598234 · Cited by 16 · see citing works
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
Shcherbinin, S., Morris, A., Higgins, I. A., Tunali, I., Lu, M., Deveau, C., Southekal, S. S., Kotari, V., Evans, C. D., Arora, A., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12415 · Cited by 15 · see citing works
Self-citationTau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
Hansen, A. K., Parbo, P., Ismail, R., Østergaard, K., Brooks, D. J., & Borghammer, P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191774 · Cited by 15 · see citing works
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 13 · see citing works
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 12 · see citing works
Visser, D., Verfaillie, S. C. J., Bosch, I., Brouwer, I., Tuncel, H., Coomans, E. M., Rikken, R. M., Mastenbroek, S. E., Golla, S. S. V., Barkhof, F., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06196-2 · Cited by 9 · see citing works
The Overlap Index as a means of evaluating early tau-PET signal reliability
Lee, J., Burkett, B. J., Min, H.-K. P., Lundt, E. S., Albertson, S. M., Botha, H., Senjem, M. L., Gunter, J. L., Schwarz, C. G., Jones, D. G., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263136 · Cited by 8 · see citing works
Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease
Atri, A., Apostolova, L. G., Iwata, A., Wessels, A. M., Atkins, A. S., Lu, M., Ye, W., Ryan, S., & Doty, E. G. (2026) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200621 · Cited by 7 · see citing works
Self-citationRecent advances in clinical trial design considerations in Thera“nostics”
Wang, S.-J. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106100 · Cited by 7 · see citing works
Senda, M., Ishii, K., Ito, K., Ikeuchi, T., Matsuda, H., Iwatsubo, T., Iwata, A., Ihara, R., Suzuki, K., Kasuga, K., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.37 · Cited by 7 · see citing works
Predicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics
Rathore, S., Higgins, I. A., Wang, J., Kennedy, I. A., Iaccarino, L., Burnham, S. C., Pontecorvo, M. J., & Shcherbinin, S. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70005 · Cited by 6 · see citing works
Self-citationAn improved preparation of [18F]AV‐45 by simplified solid‐phase extraction purification
Zhang, L., Zhang, A., Yao, X., Zhang, Y., Liu, F., Hong, H., Zha, Z., Liu, Y., Wu, Z., Qiao, J., et al. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3813 · Cited by 6 · see citing works
Lois, C., Fu, J. F., Salvatore, A. N., Garimella, A. H., Huell, D., Sari, H., Izquierdo‐Garcia, D., Mercaldo, N. D., Dickerson, B. C., Johnson, K. A., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00402 · Cited by 5 · see citing works
Development and Validation of a 18 F-Flortaucipir PET Visual Stratification Method
Tunali, I., Wang, J., Arora, A., Kim, M. J., Shcherbinin, S., Pontecorvo, M. J., & Iaccarino, L. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268700 · Cited by 5 · see citing works
Self-citationCeperognastat in Early Symptomatic Alzheimer Disease
Fleisher, A., Munsie, L. M., Mancini, M., Cheng, Y., Guo, J., Nuthall, H. N., Svaldi, D. O., Kotari, V., Kielbasa, W., Hutton, M. L., et al. (2026) · JAMA · doi:10.1001/jama.2026.12768 · Cited by 5 · see citing works
Self-citationPetersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12434 · Cited by 4 · see citing works
Self-citationLongitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia
Utianski, R. L., Botha, H., Whitwell, J. L., Martin, P. R., Schwarz, C. G., Duffy, J. R., Clark, H. M., Spychalla, A. J., Senjem, M. L., Petersen, R. C., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.04.010 · Cited by 4 · see citing works
Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
Quattrini, G., Ferrari, C., Pievani, M., Geviti, A., Ribaldi, F., Scheffler, M., Frisoni, G. B., Garibotto, V., Marizzoni, M., & Initiative, A. D. N. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06280-7 · Cited by 4 · see citing works
Ackley, S. F., Joie, R. L., Caunca, M. R., Mukherjee, S., Choi, S., Trittschuh, E. H., Crane, P. K., Hayes‐Larson, E., & Initiative, A. D. N. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag068 · Cited by 3 · see citing works
Joint EANM/SNMMI recommendations on the use of Tau PET imaging in Alzheimer's disease
Brendel, M., Kuo, P. H., Brumberg, J., Doré, V., Drzezga, A. E., Garibotto, V., Leuzy, A., Mathoux, G., Meyer, P. T., Moscoso, A., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100214 · Cited by 3 · see citing works
Self-citationRakêt, L. L., Lu, M., Evans, C. D., Zimmer, J. A., Sparks, J., Collins, E. C., Shcherbinin, S., Wang, H., Nery, E. S. M., Epelbaum, S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71577 · Cited by 3 · see citing works
Self-citationPal, S., & Melnik, R. (2025) · Quantitative Biology · doi:10.1002/qub2.70001 · Cited by 3 · see citing works
Az Alzheimer-kór molekuláris képi megjelenítése
Albert, A., & Borbély, K. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31485 · Cited by 3 · see citing works
Identifiability-Guided Assessment of Digital Twins in Alzheimer’s Disease Clinical Research and CarePreprint
Jiang, J., Petrella, J. R., Hao, W., & Initiative, T. A. D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.17.670697 · Cited by 3 · see citing works
Ikari, Y., Akamatsu, G., Matsumoto, K., Yamane, T., Senda, M., & Fukuchi, K. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.267113 · Cited by 2 · see citing works
PET Radiopharmaceutical Development
Smith-Jones, P. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_2
Genistein effect on cognition in early Alzheimer’s disease patients. The GENIAL clinical trialPreprint
Viña, J., Escudero, J. V., Baquero, M., Carbonell‐Asins, J. A., Tarazona‐Santabalbina, F. J., Cebrián, M., Muñoz, J. E., Satorres, E., Meléndez, J. C., Rebolleda, J. F., et al. (2022) · medRxiv · doi:10.1101/2022.06.01.22275832
Lam, J., Rodríguez‐Cruces, R., Arafat, T., Royer, J., Chen, J., Dascal, A., Sahlas, E., Pana, R., Hopewell, R., Hsiao, C. H.-H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.655622
Ackley, S. F., Joie, R. L., Caunca, M. R., Mukherjee, S., Choi, S., Trittschuh, E. H., Crane, P. K., Hayes‐Larson, E., & Initiative, T. A. D. N. (2025) · medRxiv · doi:10.1101/2025.11.06.25339696
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A. S., Mintun, M. A., Devous, M. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571886
Self-citationViña, J., Escudero, J., Baquero, M., Cebrián, M., Carbonell-Asíns, J. A., Muñoz, J. E., Satorres, E., Melendez, J. C., Ferrer-Rebolleda, J., Cózar-Santiago, M. D. P., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21500779
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A. S., Mintun, M. A., Devous, M. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571898
Self-citationKotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A. S., Mintun, M. A., Devous, M. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571892
Self-citationKotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A. S., Mintun, M. A., Devous, M. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571895
Self-citationKotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A. S., Mintun, M. A., Devous, M. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571889
Self-citationJoint Reconstruction of Longitudinal Positron Emission Tomography Studies for Tau Protein Imaging
Tiss, A. (2019) · theses.fr (ABES) · doi:10.70675/c487be06z4e17z48c0za864zfe62a434cd75
Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Burnham, S. C., Arora, A., Iaccarino, L., Kennedy, I. A., Kotari, V., Wijayawardana, S. R., Shaw, L. M. J., Benina, N., Lu, M., Pontecorvo, M. J., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70288
Self-citationFunctional network contributions to longitudinal tau spread in Posterior Cortical Atrophy
Katsumi, Y., Eckbo, R., McGinnis, S. M., Sepulcre, J., Rabinovici, G. D., Joie, R. L., Dickerson, B. C., & Putcha, D. (2026) · npj Dementia · doi:10.1038/s44400-026-00101-y
Han, X., Wen, S., Zhao, S., Chen, H. M., Chen, X.-L., Mou, L., Wu, Y., Wang, H., Li, S., Zhang, H., et al. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6c01111
Rial, A. M., Leuzy, A., Rakêt, L. L., Villemagne, V. L., Klein, G., Tonietto, M., Olafson, E., Smith, R., Schwarz, C. G., Baker, S. L., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71886
Self-citation
- Authors
- Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., & Mintun, M. A.
- Affiliations
- Avid Radiopharmaceuticals (United States) (US)
- Hoag Memorial Hospital Presbyterian (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-12-28
- Volume
- 59
- Issue
- 6
- Pages
- 937-943
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2780392608
- Cited by
- 79
- References
- 44
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 10 · 2021: 11 · 2020: 6 · 2019: 10 · 2018: 3 · 2017: 1
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- tau PET imaging, test-retest reproducibility, Alzheimer's disease, mild cognitive impairment, neurofibrillary tangles, standardized uptake value ratio, intraclass correlation coefficient, inter-rater reliability, [11C]PIB, 18F-florbetapir
- MeSH terms
- Aged, Alzheimer Disease, Carbolines, Female, Humans, Male, Middle Aged, Reproducibility of Results, Case-Control Studies, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
